Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Eckhardt

Showing results (71-80 of 153) with videos related to

Pageof 16
Sort By:
Neoplasma|January 1, 1977
Biopharmacological investigation of 6,6'methylene-bis/2,2,4-trimethyl-1,2-dihydroquinoline (MTDQ) a radical binding antioxidant of secondary amine typeV Bär, V Erdélyi, G Foris, et al.
Acta Radiologica: Oncology, Radiation, Physics, Biology|January 1, 1979
Basal cell carcinoma treated with MTDQ and irradiationZ Pollák, J Fodor, V Erdélyi, et al.
Nature Communications|September 16, 2016
The sources of atmospheric black carbon at a European gateway to the ArcticP Winiger, A Andersson, S Eckhardt, et al.
Neoplasma|January 1, 1975
Perspectives in scintigraphic detection of gynecologic tumors using labeled estrogenZ Szendröi, L Kocsár, B Töttössy, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 1, 1985
Phase I and II studies of cytostatic hexitol derivatives: the role of alkylating metabolites?S Eckhardt, S Kerpel-Fronius, I P Horváth, et al.
Archiv Fur Geschwulstforschung|January 1, 1975
[Investigation on radiosensitizing and tumor inhibiting actions of the antioxidant MTDQ (6,6'-methylen-bis/2,2,4-trimethyl-1-1,2-dihydroquinolin) (author's transl)]V Bär, G Foris, V Erdélyi, et al.
Oncology|January 1, 1980
Forms and results of mitolactol therapyI Hindy, J Szántó, I Bodrogi, et al.
Orvosi Hetilap|March 31, 1991
[The anti-estrogenic effect of 4-chloro-1,2-diphenyl-1-(4-[2-(N,N-dimethylamino)ethoxy]phenyl)1-butene (Toremifene) on the endocrine regulation in breast cancer patients]I Számel, I Hindy, B Vincze, et al.
Orvosi Hetilap|November 19, 1972
[Serum ceruloplasmin in malignant diseases of the hematopoietic system]I Tóth, C Sellei, O Hevér, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG)V Erdélyi-Tóth, S Kerpel-Fronius, B Kanyár, et al.
Pageof 16

Showing results (71-80 of 153) with videos related to

Sort By:
Pageof 16
Neoplasma|January 1, 1977
Biopharmacological investigation of 6,6'methylene-bis/2,2,4-trimethyl-1,2-dihydroquinoline (MTDQ) a radical binding antioxidant of secondary amine typeV Bär, V Erdélyi, G Foris, et al.
Acta Radiologica: Oncology, Radiation, Physics, Biology|January 1, 1979
Basal cell carcinoma treated with MTDQ and irradiationZ Pollák, J Fodor, V Erdélyi, et al.
Nature Communications|September 16, 2016
The sources of atmospheric black carbon at a European gateway to the ArcticP Winiger, A Andersson, S Eckhardt, et al.
Neoplasma|January 1, 1975
Perspectives in scintigraphic detection of gynecologic tumors using labeled estrogenZ Szendröi, L Kocsár, B Töttössy, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 1, 1985
Phase I and II studies of cytostatic hexitol derivatives: the role of alkylating metabolites?S Eckhardt, S Kerpel-Fronius, I P Horváth, et al.
Archiv Fur Geschwulstforschung|January 1, 1975
[Investigation on radiosensitizing and tumor inhibiting actions of the antioxidant MTDQ (6,6'-methylen-bis/2,2,4-trimethyl-1-1,2-dihydroquinolin) (author's transl)]V Bär, G Foris, V Erdélyi, et al.
Oncology|January 1, 1980
Forms and results of mitolactol therapyI Hindy, J Szántó, I Bodrogi, et al.
Orvosi Hetilap|March 31, 1991
[The anti-estrogenic effect of 4-chloro-1,2-diphenyl-1-(4-[2-(N,N-dimethylamino)ethoxy]phenyl)1-butene (Toremifene) on the endocrine regulation in breast cancer patients]I Számel, I Hindy, B Vincze, et al.
Orvosi Hetilap|November 19, 1972
[Serum ceruloplasmin in malignant diseases of the hematopoietic system]I Tóth, C Sellei, O Hevér, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG)V Erdélyi-Tóth, S Kerpel-Fronius, B Kanyár, et al.
Pageof 16